The University of Lausanne is offering this technology for licensing or for collaboration.

The technology consists of stromal cells lines of human origin, very efficient as feeder layer for hematopoietic stem cells culture

Development Phase :
Reduced to practice (lab)

Patent Status :
A provisional patent application has been filed on 14 March 2001

Patent Attorney :
Mintz & Levin, Boston, USA

Novelty and Benefits:

The novelty and advantages of this technology are manifold: the clones of stromal cell lines are of adult human origin; the high number of hematopoietic stem cell observed after 5 weeks of co-culture, which match those obtained to date with stromal cell lines of murine origin; the plasmid used, which promotes cell proliferation at 33°, but inhibits it at 37°.

Additional information is available upon request

Contact :

Marjory Hunt, PhD
tel: +41-21-314-4958
fax: +41-21-314-4957

Pactt
Office of Technology Transfer
University of Lausanne and University Hospitals
21, Rue du Bugnon
Ch-1005 Lausanne
e-mail: marjory.hunt@hospvd.ch

Generation of Stromal Cell Lines from Human Bone Marrow

(Ref. Number IDF 5.01)

The Technology :
Marrow stromal cells play a vital role in the subsistence, growth and differentiation of hematopoietic stem cells. These cells are therefore of great interest as feeder layer for the growth of hematopoietic stem cells.

To this day, the immortalized human stromal cell lines are not optimal for the proliferation of hematopoietic stem cells, more specifically for the production of viable hematopoietic stem cell clones.

We propose stromal cells lines of human origin, which have the ability to maintain undifferentiated hematopoietic stem cells in vitro with high number of colony-forming cells. Cell immortalization is achieved using a mutant of the SV40 large T antigen.

Applications :
This technology should be of interest to Pharmaceutical and Biotechnology companies involved in the production of human hematopoietic stem cell for bone marrow transplant, tissue (connective, bone) engineering, as well as for research and development related to somatic gene therapy (ex vivo or in vivo).